Calcitonin gene-related peptide-targeting drugs and Raynaud's phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database.
Adverse drug reaction
CGRP receptor
CGRP receptor antagonist antibody
CGRP-targeting drugs
Calcitonin gene-related peptide
Gepants
Migraine
Pharmacovigilance
Raynaud’s phenomenon
Journal
The journal of headache and pain
ISSN: 1129-2377
Titre abrégé: J Headache Pain
Pays: England
ID NLM: 100940562
Informations de publication
Date de publication:
03 May 2022
03 May 2022
Historique:
received:
26
03
2022
accepted:
27
04
2022
entrez:
3
5
2022
pubmed:
4
5
2022
medline:
6
5
2022
Statut:
epublish
Résumé
Migraine is responsible for significant disability and societal burden. Recently, drugs targeting the calcitonin gene-related peptide (CGRP) pathway raised new hopes. CGRP, a potent vasodilator, plays a key role in the pathogenesis of migraine attacks. The deficiency of CGRP is involved in Raynaud's phenomenon, which consists of abnormal vasoconstriction of the digits. We aimed to assess the potential association of Raynaud's phenomenon with CGRP-targeting drugs, analyzing real-world data from the World Health Organization (VigiBase®). We queried all reports of Raynaud's phenomenon involving a CGRP-targeting drug. We sought disproportionate reporting of Raynaud's phenomenon with these drugs. For this purpose, we relied on the calculation of the Information Component (IC). A positive lower end of the 95% confidence interval (CI) of the IC defines a statistically significant association. As migraine patients are prone to Raynaud's phenomenon, we also calculated the IC of Raynaud's phenomenon with CGRP-targeting drugs compared to 5HT1 Overall, 99 reports of Raynaud's phenomenon involving CGRP-targeting drugs have been yielded in VigiBase®. The most reported CGRP-targeting drug was erenumab, with 56 reports (56.6%). The median time to onset was 84 days. No fatality was notified, but one patient suffered from gangrene and extremity necrosis. As a whole, CGRP-targeting drugs were significantly associated with Raynaud's phenomenon, with an IC of 3.3 (95%CI: 3.0-3.5). There was a disproportionate reporting of Raynaud's phenomenon with CGRP-targeting drugs compared to triptans (IC 0.4; 95%CI: 0.1-0.6) and to beta-blockers (IC 0.5; 95%CI: 0.2-0.7) as well. There is a significant disproportionality signal of Raynaud's phenomenon with CGRP-targeting. This signal stands out when CGRP-targeting drugs are compared to other drugs used in patients with migraine. This study is limited by missing data in pharmacovigilance reports. CGRP-targeting drugs may be subject to Weber effect and reporting bias. Nonetheless, CGRP blockade might be the last straw that disrupts the physiological balance of vascular response in patients at-risk of Raynaud's phenomenon. Pending further data regarding vascular safety of CGRP-targeting drugs, caution is warranted in these patients.
Sections du résumé
BACKGROUND
BACKGROUND
Migraine is responsible for significant disability and societal burden. Recently, drugs targeting the calcitonin gene-related peptide (CGRP) pathway raised new hopes. CGRP, a potent vasodilator, plays a key role in the pathogenesis of migraine attacks. The deficiency of CGRP is involved in Raynaud's phenomenon, which consists of abnormal vasoconstriction of the digits. We aimed to assess the potential association of Raynaud's phenomenon with CGRP-targeting drugs, analyzing real-world data from the World Health Organization (VigiBase®).
METHODS
METHODS
We queried all reports of Raynaud's phenomenon involving a CGRP-targeting drug. We sought disproportionate reporting of Raynaud's phenomenon with these drugs. For this purpose, we relied on the calculation of the Information Component (IC). A positive lower end of the 95% confidence interval (CI) of the IC defines a statistically significant association. As migraine patients are prone to Raynaud's phenomenon, we also calculated the IC of Raynaud's phenomenon with CGRP-targeting drugs compared to 5HT1
RESULTS
RESULTS
Overall, 99 reports of Raynaud's phenomenon involving CGRP-targeting drugs have been yielded in VigiBase®. The most reported CGRP-targeting drug was erenumab, with 56 reports (56.6%). The median time to onset was 84 days. No fatality was notified, but one patient suffered from gangrene and extremity necrosis. As a whole, CGRP-targeting drugs were significantly associated with Raynaud's phenomenon, with an IC of 3.3 (95%CI: 3.0-3.5). There was a disproportionate reporting of Raynaud's phenomenon with CGRP-targeting drugs compared to triptans (IC 0.4; 95%CI: 0.1-0.6) and to beta-blockers (IC 0.5; 95%CI: 0.2-0.7) as well.
CONCLUSIONS
CONCLUSIONS
There is a significant disproportionality signal of Raynaud's phenomenon with CGRP-targeting. This signal stands out when CGRP-targeting drugs are compared to other drugs used in patients with migraine. This study is limited by missing data in pharmacovigilance reports. CGRP-targeting drugs may be subject to Weber effect and reporting bias. Nonetheless, CGRP blockade might be the last straw that disrupts the physiological balance of vascular response in patients at-risk of Raynaud's phenomenon. Pending further data regarding vascular safety of CGRP-targeting drugs, caution is warranted in these patients.
Identifiants
pubmed: 35505285
doi: 10.1186/s10194-022-01424-w
pii: 10.1186/s10194-022-01424-w
pmc: PMC9066820
doi:
Substances chimiques
Tryptamines
0
Calcitonin Gene-Related Peptide
JHB2QIZ69Z
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
53Informations de copyright
© 2022. The Author(s).
Références
J Headache Pain. 2019 Mar 12;20(1):27
pubmed: 30866804
Lancet. 1993 Jul 10;342(8863):80-3
pubmed: 8100913
JAMA Netw Open. 2021 Apr 1;4(4):e217934
pubmed: 33871613
Arthritis Rheum. 2005 Apr;52(4):1259-63
pubmed: 15818710
Drug Saf. 2007;30(10):891-8
pubmed: 17867726
Br J Dermatol. 1996 Mar;134(3):399-406
pubmed: 8731660
J Headache Pain. 2014 Feb 08;15:7
pubmed: 24506953
Eur J Clin Pharmacol. 1998 Jun;54(4):315-21
pubmed: 9696956
Headache. 2007 Apr;47(4):475-9
pubmed: 17445096
Lancet Neurol. 2022 Mar;21(3):284-294
pubmed: 35093196
Pharmacoepidemiol Drug Saf. 2009 Jun;18(6):427-36
pubmed: 19358225
Curr Pain Headache Rep. 2019 Mar 14;23(5):29
pubmed: 30874961
Handb Exp Pharmacol. 2019;255:131-140
pubmed: 30879200
Presse Med. 1994 Feb 5;23(4):171-5
pubmed: 8177860
Eur J Dermatol. 2018 Jun 1;28(3):364-369
pubmed: 29952300
Clin Case Rep. 2021 Aug 16;9(8):e04625
pubmed: 34430000
Arch Intern Med. 1984 Apr;144(4):742-4
pubmed: 6143540
N Engl J Med. 2017 Nov 30;377(22):2123-2132
pubmed: 29171821
Lancet. 2017 Sep 16;390(10100):1211-1259
pubmed: 28919117
Cephalalgia. 2019 Sep;39(10):1284-1297
pubmed: 30917684
Drug Saf. 2001;24(3):233-7
pubmed: 11347725
Circulation. 1994 Jan;89(1):366-74
pubmed: 8281672
Headache. 2015 Jan;55(1):21-34
pubmed: 25600719
Neurology. 2020 Feb 4;94(5):e497-e510
pubmed: 31852816
Clin Ther. 2022 Feb;44(2):306-322
pubmed: 35074209
Headache. 2019 Sep;59(8):1360-1364
pubmed: 31310337
Lancet Neurol. 2016 Apr;15(4):382-90
pubmed: 26879279
Nat Rev Neurol. 2019 Nov;15(11):627-643
pubmed: 31586135
Headache. 2018 Sep;58(8):1277-1286
pubmed: 30117565
Physiol Rev. 2014 Oct;94(4):1099-142
pubmed: 25287861
Stat Methods Med Res. 2013 Feb;22(1):57-69
pubmed: 21705438
Neuroreport. 1996 Aug 12;7(12):1973-6
pubmed: 8905706
Br J Clin Pharmacol. 2016 Jul;82(1):6-16
pubmed: 26949933
Pharmacotherapy. 2004 Jun;24(6):743-9
pubmed: 15222664
JAMA. 2020 Jun 9;323(22):2281-2289
pubmed: 32515815
JAMA Intern Med. 2021 Sep 1;181(9):1243-1245
pubmed: 33904857
Lancet. 1990 Dec 22-29;336(8730):1530-3
pubmed: 1979366
Pharmacol Ther. 2020 Jul;211:107528
pubmed: 32173558
J Neurol Neurosurg Psychiatry. 2020 Jun;91(6):593-604
pubmed: 32217787
J Headache Pain. 2022 Jan 29;23(1):19
pubmed: 35093013
J Headache Pain. 2013 Jan 10;14:1
pubmed: 23566305
Pharmacol Ther. 2009 Dec;124(3):309-23
pubmed: 19796656
Br Med J. 1976 Jun 19;1(6024):1498-9
pubmed: 6109
Lancet Neurol. 2022 Mar;21(3):209-210
pubmed: 35093197
Cephalalgia. 2019 Dec;39(14):1731-1734
pubmed: 31526030
Lancet Oncol. 2018 Dec;19(12):1579-1589
pubmed: 30442497
J Headache Pain. 2021 Jul 14;22(1):71
pubmed: 34261435
Ann Rheum Dis. 2000 Mar;59(3):206-10
pubmed: 10700429
Nat Rev Neurol. 2018 Jun;14(6):338-350
pubmed: 29691490